Clinical Trial Update: The Study is Being Done to See if Taking the Drug Valganciclovir Can Prevent CMV Infection. [Phase 3]

View source ↗

Summary

A Phase 3 trial tested whether valganciclovir prevents cytomegalovirus infections in bone marrow/stem cell transplant recipients. The study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytomegalovirus Infections

Drugs mentioned

• Valcyte (valganciclovir)

Snippet

Sponsor: Mayo Clinic | Conditions: Bone Marrow Stem Cell Transplant | Phase 3 | Status: COMPLETED